These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 35249367)

  • 1. Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
    Carvalhaes CG; Klauer AL; Rhomberg PR; Pfaller MA; Castanheira M
    J Clin Microbiol; 2022 Apr; 60(4):e0244921. PubMed ID: 35249367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
    Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
    Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
    J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
    Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
    J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
    Castanheira M; Deshpande LM; Messer SA; Rhomberg PR; Pfaller MA
    Int J Antimicrob Agents; 2020 Jan; 55(1):105799. PubMed ID: 31520783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Int J Antimicrob Agents; 2017 Sep; 50(3):352-358. PubMed ID: 28689871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
    Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
    Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
    Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae.
    Tóth Z; Forgács L; Locke JB; Kardos G; Nagy F; Kovács R; Szekely A; Borman AM; Majoros L
    J Antimicrob Chemother; 2019 Dec; 74(12):3505-3510. PubMed ID: 31539426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.
    Arendrup MC; Jørgensen KM; Hare RK; Cuenca-Estrella M; Zaragoza O
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rezafungin
    Helleberg M; Jørgensen KM; Hare RK; Datcu R; Chowdhary A; Arendrup MC
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints.
    Chen YC; Kuo SF; Chen FJ; Lee CH
    Mycoses; 2017 Feb; 60(2):89-95. PubMed ID: 27621210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
    Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA
    Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.
    Carvalhaes CG; Rhomberg PR; Pfaller MA; Locke JB; Castanheira M
    Mycoses; 2022 Nov; 65(11):1040-1044. PubMed ID: 35778886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020).
    Pfaller MA; Huband MD; Rhomberg PR; Bien PA; Castanheira M
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0102822. PubMed ID: 36286491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.